Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Dose Ranging, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis

NCT01837420 is registered in ClinicalTrials.gov with Vascular Biogenics Ltd. operating as VBL Therapeutics as lead sponsor.

NCT NCT01837420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01837420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Dose Ranging, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2012
Completion date
November 30, 2014
Enrollment
194 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis